What are the common side effects of giritinib? How to deal with adverse reactions

Gilteritinib is a targeted therapy drug mainly used to treat acute myeloid leukemia (AML), especially patients with positive FLT3 gene mutations. Although giritinib has a significant effect on improving the prognosis of AML patients, it may also cause some side effects. Understanding these side effects and taking appropriate management measures can help patients better cope with the treatment process, improve efficacy and reduce discomfort.

Common side effects of giritinib include liver damage, gastrointestinal discomfort, hematological abnormalities, andQT interval prolongation. Liver damage is one of the most common adverse effects of giritinib. It may manifest as elevated liver enzymes (such as ALT and AST), which may indicate some damage to the liver. In this case, the doctor will usually order periodic liver function tests. If liver function is abnormal, the drug may need to be temporarily discontinued or the dose reduced until liver enzyme levels recover before continuing treatment. In addition, it is crucial to avoid concurrent use of drugs that may burden the liver and to regularly monitor liver function.

Another common side effect is gastrointestinal discomfort, which can include symptoms such as nausea, vomiting, loss of appetite, and diarrhea. These gastrointestinal symptoms usually occur early in treatment and may improve over time. To alleviate these discomforts, patients can choose to take gilitinib after a meal instead of taking it on an empty stomach. If symptoms are severe, your doctor may adjust the dose or provide symptomatic treatment with medications, such as antiemetics or antidiarrheal medications.

Hematological abnormalities are another important side effect of giritinib treatment. Especially in the initial stage, giritinib may cause neutropenia, anemia or thrombocytopenia, which increase the risk of infection, bleeding and other problems. For this reason, patients need to undergo regular blood tests and monitor blood cell counts during treatment.

Reference materials:https://www.xospata.com/